The role of novel biomarkers of cardiovascular disease in chronic kidney disease: Focus on adiponectin and leptin

Current Cardiology Reviews

Volumn 4, Issue 4, 2008, Pages 287-292

  Kaisar, Omar M ^a   Johnson, David W ^a   Prins, Judith B ^a   Isbel, Nicole ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Adiponectin; Biomarker; Cardiovascular disease; Kidney disease; Leptin

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE TRANSPORTER 4; INTERLEUKIN 6; JANUS KINASE; LEPTIN; NITRIC OXIDE; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA;

ATHEROGENESIS; CACHEXIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DISEASE MARKER; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART PROTECTION; HEMODIALYSIS; HORMONE ACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; MORTALITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 65649103736     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340308786349516     Document Type: Review

References (96)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S9.
2. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-15.
3. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1(1): 8-18.
4. Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-95.
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305
6. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164(6): 659-63.
7. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296: 1377-84.
8. Kaisar MO, Isbel NM, Johnson DW. Cardiovascular disease in patients with chronic kidney disease: A clinical review. Minerva Urologica e Nefrologica 2007; 59(3): 281-97.
9. Kaisar MO, Isbel NM, Johnson DW. Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. Rev Recent Clin Trials 2008; 3(2): 79-88.
10. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-8.
11. Ejerblad E, Fored M, Lindblad P, McLaughlin JK, Nyrén O. Obesity and risk of chronic renal failure. J Am Soc Nephrol 2006; 17:1695-702.
12. Rabin KR, Kamari Y, Avni I, Grossman E, Sharabi Y. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 2005; 3(3): 465-71.
13. Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29(6): 1357-62.
14. Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004; 94:27-31.
15. Whitehead JP, Richards AA, Hickman IJ, MacDonald GA, Prins JB. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8(3): 264-80.
16. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6): 1595-99.
17. Iwashima Y, Katsuya T, Ishikawa K, et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension 2005; 45(6): 1094-100.
18. Dzielińska Z, Januszewicz A, Wiecek A, et al. Decreased plasma concentration of a novel anti-inflammatory protein adiponectin in hypertensive men with coronary artery disease. Thromb Res 2003; 110(5-6): 365-9.
19. Zoccali C, Mallamaci F, Panuccio V, et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl 2003; (84): S98-102.
20. Zoccali C, Mallamaci F. Adiponectin and renal disease progression: another epidemiologic conundrum? Kidney Int 2007; 71(12): 1195-7.
21. Kumada M, Khihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23(1): 85-9.
22. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13(1): 134-41.
23. Becker B, Kronenberg F, Kielstein JT, et al. MMKD Study Group. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16(4): 1091-8.
24. Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 2006; 98(12): 1603-8.
25. Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronickidney disease. J Am Soc Nephrol 2006; 17(9): 2599-606.
26. Nishimura M, Hashimoto T, Kobayashi H, et al. Association of the circulating adiponectin concentration with coronary in-stent restenosis in haemodialysis patients. Nephrol Dial Transplant 2006; 21(6): 1640-7.
27. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
28. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005; 46: 1369-79.
29. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46(4): 459-69.
30. Mantzoros CS, Li T, Manson JE, Meigs JB, Fu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005; 90(8): 4542-48.
31. van der Vleuten, van Tits LJ, den Heijer M, Lemmers H, Stalenhoef AF, de Graff J. Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile. J Lipid Res 2005; 46(11): 2398-404.
32. Xu A, Yin S, Wong L, Chan KW, Lam KS. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 2004; 145(2): 487-94.
33. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671-74.
34. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52: 1779-85.
35. Krakoff J, Funahashi T, Stehouwer CD, et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 1745-51.
36. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-301.
37. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein. Circulation 1999; 100: 2473-6.
38. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109: 2046-9.
39. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates nitric oxide production in vascular endothelial cells. J Biol Chem 2003; 278: 45021-6.
40. Koh K, Quon M, Han S, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005; 45: 1088-93.
41. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinedione on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-74.
42. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110:3687-92.
43. Yenicesu M, Yilmaz MI, Caglar K, et al. Blockade of the renin-angiotensin system increases plasma adiponectin concentration in type 2 diabetic patients with proteinuria. Nephron Clin Pract 2005; 99: 115-21.
44. Furuya R, Odamaki M, Kumagai H, Hishida A. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif 2006; 24: 445-50.
45. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
46. Fried SK, Ricci MR, Russell CD, Laferrère B. Regulation of leptin production in humans. J Nutr 2000; 130: 3127S-31S.
47. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-95.
48. Vaisse C, Halaas JL, Horvath CM, Darnell JE Jr, Stoffel M, Friedman JM. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 1996; 14: 95-7.
49. Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001; 411: 480-4.
50. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-71.
51. Bjorbaek C, Buchholz RM, Davis SM, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001; 276: 4747- 55.
52. Munzberg H, Myers MG Jr. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 2005; 8: 566-70.
53. Banks WA. Blood-brain barrier and energy balance. Obesity (Spring) 2006; 14(suppl 5): 234S-7S.
54. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31: 409-14.
55. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000; 105: 1243-52.
56. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100: 270-8.
57. Shibuya I, Utsunomiya K, Toyohira Y, et al. Regulation of catecholamine synthesis by leptin. Ann N Y Acad Sci 2002; 971: 522-7.
58. Beltowski J, Wocicka G, Gorny D, Marciniak A. Human leptin administered intraperitoneally stimulates natriuresis and decreases renal medullary Na+ K+-ATPase activity in the rat - impaired effect in dietary-induced obesity. Med Sci Monit 2002; 8: 221-9.
59. Villarreal D, Reams G, Freeman RH. Effects of renal denervation on the sodium excretory actions of leptin in hypertensive rats. Kidney Int 2002; 58: 989-94.
60. Agata J, Masuda A, Takada M, et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997; 10: 1171-4.
61. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072-9.
62. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001; 25(6): 805-10.
63. Singhal A, Farooqi IS, Cole TJ, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 2002; 106(15): 1919-24.
64. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003; 157(1): 25-31.
65. Oflaz H, Ozbey N, Mantar F, et al. Determination of endothelial function and early atherosclerotic changes in healthy obese women. Diabetes Nutr Metab 2003; 16: 176-81.
66. Reilly MP, Iqbal N, Schutta M, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 3872-8.
67. Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246: 409-18.
68. Wallerstedt SM, Eriksson AL, Niklason A, Ohlsson C, Hedner T. Serum leptin and myocardial infarction in hypertension. Blood Press 2004; 13: 243-6.
69. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104(25): 3052-6.
70. Schulze PC, Kratzsch J, Linke A, et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 2003; 5(1): 33-40.
71. Perego L, Pizzocri P, Corradi D, et al. Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy. J Clin Endocrinol Metab 2005; 90(7): 4087-93.
72. Soderberg S, Stegmayr B, Stenlund H, et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med 2004; 256: 128-36.
73. Söderberg S, Ahrén B, Stegmayr B. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 1999; 30(2): 328-37.
74. Bełtowski J, W'ojcicka G, Marciniak A, Jamroz A. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci 2004; 74: 2987-3000.
75. Bełtowski J, W'ojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003; 170: 21-9.
76. Watson AM, Poloyac SM, Howard G, Blouin RA. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos 1999; 27: 695-700.
77. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999; 48: 903-8.
78. Raso GM, Pacilio M, Esposito E, et al. Leptin potentiates IFN-gamma induced expression of nitric oxide synthase and cyclooxygenase-2 in murine macrophage J774A.1. Br J Pharmacol 2002; 137: 799-804.
79. Piatti P, Di Mario C, Monti LD, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with instent restenosis in patients undergoing coronary stenting. Circulation 2003; 108: 2074-81.
80. Corsonello A, Malara A, De Domenico D, et al. Identifying pathways involved in leptin-dependent aggregation of human platelets. Int J Obes Relat Metab Disord 2004; 28: 979-84.
81. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394(6696): 897-901.
82. Rajapurohitam V, Javadov S, Purdham DM, Kirshenbaum LA, Karmazyn M. An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1. J Mol Cell Cardiol 2006; 41: 265-74.
83. Nickola MW, Wold LE, Colligan PB, Wang GJ, Samson WK, Ren J. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 2000; 36: 501-5.
84. Pecoits-Filho R, Nordfors L, Heimburger O, et al. Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur J Clin Invest 2002; 32: 811-7.
85. Merabet E, Dagogo-Jack S, Coyne DW, et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1997; 82(3): 847-50.
86. Diez JJ, Iglesias P, Fernandez-Reyes MJ, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol 2005; 62: 242-9.
87. Mak RH, Cheung W, Cone RD, Marks DL. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int 2006; 69: 794-7.
88. Teta D, Bevington A, Brown J, Pawluczyk I, Harris K, Walls J. Acidosis downregulates leptin production from cultured adipocytes through a glucose transport-dependent posttranscriptional mechanism. J Am Soc Nephrol 2003; 14: 2248-54.
89. Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998; 54: 1267-75.
90. Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996; 97: 2152-7.
91. Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol 1998; 9: 1080-4.
92. Aguilera A, Bajo MA, Rebollo F, et al. Leptin as a marker of nutrition and cardiovascular risk in peritoneal dialysis patients. Adv Perit Dial 2002; 18: 212-7.
93. Nasri H. Serum leptin concentration and left ventricular hypertrophy and function in maintenance hemodialysis patients. Minerva Urol Nefrol 2006; 58: 189-93.
94. Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring). 2007; 15(6): 1617-22.
95. Don BR, Rosales LM, Levine NW, Mitch W, Kaysen GA. Leptin is a negative acute phase protein in chronic hemodialysis patients. Kidney Int 2001; 59: 1114-20.
96. Hung SC, Tung TY, Yang CS, Tarng DC. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients. Am J Kidney Dis 2005; 45: 1073-83.